当前位置:
X-MOL 学术
›
Curr. Opin. Mol. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Drug evaluation: the C5a receptor antagonist PMX-53.
Current opinion in molecular therapeutics Pub Date : 2007-01-25 Jörg Köhl 1
Current opinion in molecular therapeutics Pub Date : 2007-01-25 Jörg Köhl 1
Affiliation
Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.
中文翻译:
药物评估:C5a受体拮抗剂PMX-53。
Peptech正在开发PMX-53,一种补体C5a抑制剂,可潜在治疗炎症性疾病,包括类风湿性关节炎和牛皮癣。两种适应症的Ib / IIa期临床试验均已完成。
更新日期:2019-11-01
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
药物评估:C5a受体拮抗剂PMX-53。
Peptech正在开发PMX-53,一种补体C5a抑制剂,可潜在治疗炎症性疾病,包括类风湿性关节炎和牛皮癣。两种适应症的Ib / IIa期临床试验均已完成。